Spire Healthcare Group PLC · LSE:SPI

Spire Healthcare — H1 2019 Earnings Presentation

42 slides from Spire Healthcare's earnings presentation, Sep 16, 2019

  1. Slide 1: H1 19 Results Presentation

    H119 Results Presentation 16 September 2019

  2. Slide 2: Disclaimer

    Disclaimer These materials contain certain forward-looking statements relating to the business of Spire Healthcare Group plc (the “Company”), including with respect to the progress, timing and completion of the Company’s development, the Company’s ability to treat, attract, and retain patients and c

  3. Slide 3: Agenda

    Agenda H1 19 Overview Justin Ash, Chief Executive Officer H1 19 Financial Review Jitesh Sodha, Chief Financial Officer Operations and Strategy Review Justin Ash, Chief Executive Officer Q&A 3

  4. Slide 4: H1 19 Overview

    H1 19 Overview Justin Ash, Chief Executive Officer

  5. Slide 5: Our strategy

    Our strategy First Choice Uncompromising on for Private Patients, Clinical Quality and NHS Key Partner Patient Safety Improving revenue, profit and cash 5

  6. Slide 6: H1 19 Overview: Delivering on strategy

    H1 19 Overview Delivering on strategy First choice for private Uncompromising on Improving revenue, NHS key partner patients patient safety profit and cash • Robust private • Return to growth • Regulatory regime • Strong revenue growth of 4.1% despite continued intensifying growth pressure on • Reco

  7. Slide 7: H1 19 Financial Review

    H1 19 Financial Review Jitesh Sodha, Chief Financial Officer

  8. Slide 8: H1 19 highlights

    H1 19 highlights EBITDA in-line with Revenue growth Cash generative Operating profit up expectations 8

  9. Slide 9: Financial Headlines H1 19: in-line with expectations

    Financial Headlines H1 19: in-line with expectations 3.4% revenue Interim dividend Operating profit EPS 1.8p growth to 1.3p per share £51.0m £491.6m (H1 18: 0.5p) (H1 18: £37.2m) (H1 18: 1.3p) (H1 18: £475.6m) EBITDA pre- Net bank debt Net debt to EBITDA EBITDA £96.8m, IFRS16 £63.7m, decreased to fo

  10. Slide 10: Revenue growth in all three payor groups

    Revenue growth in all three payor groups Revenue (£m) 5.1% 234.9 247.0 Private 4.1% 87.4 88.6 1.4% 140.3 143.7 2.5% H1 18 H1 19 NHS Self-pay PMI Other 10

  11. Slide 11: Revenue growth in all three payor groups

    Revenue growth in all three payor groups % change in H1 19 vs IPDC ARPC IPDC Outpatient Total H1 18 volume revenue revenue revenue PMI 0.8% 4.6% 5.4% 4.7% 5.1% Self-pay (1.9%) 2.8% 0.9% 3.2% 1.4% Total private 0.0% 3.9% 4.0% 4.4% 4.1% NHS (3.5%) 5.6% 1.8% 4.9% 2.5% Total (1.3%) 4.6% 3.2% 4.5% 3.4% 1

  12. Slide 12: Revenue growth offset by planned investments

    Revenue growth offset by planned investments £66.1m £63.7m H1 18 EBITDA* IPDC volume IPDC Mix / Outpatient Hospital costs Other H1 19 EBITDA* Price * EBITDA pre IFRS 16 12

  13. Slide 13: Operating profit bridge

    Operating profit bridge £30.3m £16.3m H1 18 D&A Exceptionals IPDC volume IPDC mix/price Outpatient Hospital costs Other H1 19 Operating profit Operating profit 13

  14. Slide 14: Planned cost investment and efficiencies

    Planned cost investment and efficiencies What we’ve achieved Work in progress • Full year impact of PY cost investments • Further procurement opportunities through • Procurement savings on consumables standardisation • Working to reduce agency costs • Share save scheme launched for first time • Accr

  15. Slide 15: Cash positive

    Cash positive H1 2019 (£m) Cash from operating activities 97.0 Working Capital Movement (11.8) Capex (21.5) Financing activities (excl. dividends) (45.0) Dividends Paid (1.3p per share) (10.0) Other (2.0) Increase in cash 10.7 15

  16. Slide 16: Solid financial headroom

    Solid financial headroom June 19 (£m) June 18 (£m) Bank Borrowings 420.6 426.1 Cash 58.4 45.1 Net bank debt 362.2 381.0 June 19 (£m) June 18 (£m) Bank Borrowings 420.6 426.1 Lease Liabilities (under IFRS 16) 721.2 730.9 Total Borrowings 1141.8 1157.0 Covenant leverage 3.3x EBITDA at June 19 (3.3x at

  17. Slide 17: H1 19 summary

    H1 19 summary Cash generative, net FY guidance 3.4% revenue growth Operating profit up bank debt reduced reiterated 17

  18. Slide 18: Operations and Strategy Review

    Operations and Strategy Review Justin Ash, Chief Executive Officer

  19. Slide 19: Strategic focus

    Strategic focus Delivering on strategy First choice for Improving NHS key Uncompromising private revenue, profit partner on patient safety patients and cash 19

  20. Slide 20: Sustained improvement in private revenue growth

    Sustained improvement in private revenue growth H1 private revenue (£m) and growth H2 private revenue (£m) and growth 340.0 4.1% 315.0 4.1% 310.0 330.0 2.8% 305.0 320.0 1.9% 2.5% 300.0 295.0 0.3% 310.0 2.4% 290.0 300.0 285.0 290.0 280.0 H1 16 H1 17 H1 18 H1 19 H2 16 H2 17 H2 18 H2 19 20

  21. Slide 21: Growth in PMI and self-pay

    Growth in PMI and self-pay PMI +5.1% Self-pay +1.4% • Capitalised on new contract wins • Marketing campaigns driving 19% growth in • Long term pricing agreements signed with enquiries and 7% growth in first outpatient Bupa and AXA PPP Healthcare appointments • Third national marketing campaign launc

  22. Slide 22: Growth in outpatient first appointments by payor

    Growth in outpatient first appointments by payor PMI Self-Pay NHS Total 15.0% 10.0% 5.0% 0.0% H1 16 H2 16 H1 17 H2 17 H1 18 H2 18 H1 19 -5.0% -10.0% 22

  23. Slide 23: Growth in outpatients

    Growth in outpatients • We are directing more resources to outpatients in response to marketing feedback: patients want to know “what is wrong with me” quickly • Purchased property to develop outpatient and imaging department next to Spire Yale • Spire GP appointments up 40% • Strong conversion of G

  24. Slide 24: Developing our oncology business

    Developing our oncology business • Oncology is an important specialty with significant potential for profitable expansion • Total oncology revenues rose 15% in H1 19, essentially all PMI • Low margin but strong cash profit per patient • Working with GenesisCare to develop a national end to end priva

  25. Slide 25: NHS waiting list is at a five year high

    NHS waiting list is at a five year high Orthopaedic waiting list at 511,000 patients 4.6 2015 2016 2017 2018 2019 Patients waiting for treatment (m) 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Source: NHS England 25

  26. Slide 26: Spire: total NHS e-referrals up 10%, NHS orthopaedic referrals stable

    Spire: total NHS e-referrals up 10%, NHS orthopaedic referrals stable All specialties Orthopaedics 25.0% 25.0% 20.0% 20.0% 15.0% 15.0% 10.0% 10.0% 5.0% 5.0% 0.0% 0.0% H1 15 H2 15 H1 16 H2 16 H1 17 H2 17 H1 18 H2 18 H1 19 H1 15 H2 15 H1 16 H2 16 H1 17 H2 17 H1 18 H2 18 H1 19 -5.0% -5.0% -10.0% e-refe

  27. Slide 27: Remaining a key partner to the NHS

    Remaining a key partner to the NHS • Rationing and triage is continuing, but there is significant geographical variation • IPDC admissions down 3.5% • New treatment protocols impacting mix • Positive tariff impact, approximately 2.5% in period • Opening new service lines • Continued gradual improvem

  28. Slide 28: Uncompromising on patient safety

    Uncompromising on patient safety • CQC inspections increasing in frequency, now covering sites already rated Good and RI • 6 sites inspected in H1 • 81% of sites rated Good, Outstanding or equivalent • 5 Outstanding sites • Working with Professor Tim Briggs on GIRFT initiative • Working closely with

  29. Slide 29: Continued focus on efficiency, patient and consultant experience

    Continued focus on efficiency, patient and consultant experience • Quality investments now largely complete • Efficiency program gaining momentum • Digital strategy key to future • Multiple patient and consultant digital platforms launched • Manchester and St Antony’s delivering profit growth, Notti

  30. Slide 30: Purpose driven by consumer insight

    Purpose driven by consumer insight Making a positive difference to our patients’ lives through outstanding personalised care 30

  31. Slide 31: Summary

    Summary Making a positive difference to our patients’ lives through outstanding personalised care Positive changes to Remain focussed on Good progress in H1 Guidance reiterated drive future quality profitable growth 31

  32. Slide 32: Appendix

    S2 Spire Healthcare Appendix Covking after yee

  33. Slide 33: Financial Headlines H1 19 – pre IFRS16

    Financial Headlines H1 19 – pre IFRS16 3.4% revenue Operating profit growth to EPS 3.4p £30.3m £491.6m (H1 18: 2.0p) (H1 18: £16.3m) (H1 18: £475.6m) EBITDA £63.7m, Net debt decreased Interim dividend 13.0% margin to £362.2m 1.3p per share (H1 18: £66.1m, 13.9% (H1 18: £381.0m, FY18: (H1 18: 1.3p) £

  34. Slide 34: Private growth

    Private growth H1 19 H1 18 Variance PMI Self-pay Total private PMI Self-pay Total private PMI Self-pay Total private IPDC admissions 61.6 23.5 85.2 61.1 24.0 85.1 0.8% (1.9%) 0.0% ARPC (£) 2,514 2,905 2,622 2,404 2,826 2,523 4.6% 2.8% 3.9% IPDC revenue (£m) 154.9 68.4 223.3 147.0 67.8 214.8 5.4% 0.9

  35. Slide 35: Total growth across all payor groups

    Total growth across all payor groups H1 19 H1 18 Variance Total private NHS Total Total private NHS Total Total private NHS Total IPDC admissions 85.2 46.8 132.0 85.1 48.5 133.7 0.0% (3.5%) (1.3%) ARPC (£) 2,622 2,404 2,545 2,523 2,277 2,434 3.9% 5.6% 4.6% IPDC revenue (£m) 223.3 112.5 335.8 214.8 1

  36. Slide 36: NHS revenue in detail

    NHS revenue in detail H1 2019 (£m) H1 2018 (£m) Variance (%) E-referral 127.5 122.8 3.9% Local 16.2 17.5 (7.3%) Total NHS revenue 143.7 140.3 2.5% 36

  37. Slide 37: EBITDA to Operating Profit

    EBITDA to Operating Profit Pre-IFRS 16 H1 2019 (£m) H1 2018 (£m) EBITDA 63.7 66.1 Depreciation (incl. profit/loss on PPE disposals) (33.0) (34.5) Exceptional items (0.4) (15.3)* Operating profit 30.3 16.3 Post-IFRS 16 H1 2019 (£m) H1 2018 (£m) EBITDA 96.8 98.9 Depreciation (incl. profit/loss on PPE

  38. Slide 38: Cash surplus after capex and dividend – pre IFRS16

    Cash surplus after capex and dividend – pre IFRS16 H1 2019 H1 2018 £m £m EBITDA 63.7 66.1 Operating cash flow before exceptionals and tax 52.2 62.2 Capex (21.5) (33.5) Exceptional items (0.1) (1.4) Financing activities (excl. dividends) (11.9) (10.1) Dividends Paid (1.3p per share) (10.0) (10.0) Oth

  39. Slide 39: Exceptional costs and lower tax driving profit growth post IFRS 16

    Exceptional costs and lower tax driving profit growth post IFRS 16 H1 2019 (£m) H1 2018 (£m) EBITDA 96.8 98.9 Depreciation, amortisation & profit/loss on disposal (45.4) (46.4) Total exceptional and other costs before taxation (0.4) (15.3) Tax credit on exceptional and other costs 0.1 7.1 Net financ

  40. Slide 40: Balance sheet

    Balance sheet June 19 (£m) Dec 18 (£m) Fixed Assets 1,540.2 1,578.4 Goodwill 517.8 517.8 Inventory 31.7 29.4 Trade and other receivables 104.7 94.2 Cash and cash equivalents 58.4 47.7 Other current assets 14.4 4.0 TOTAL ASSETS 2,267.2 2,271.5 Bank Borrowings 420.6 420.4 Lease Liabilities 721.2 726.1

  41. Slide 41: FY19 technical guidance

    FY19 technical guidance Continued revenue growth, offset by mix and planned investments Revenue Private growth with emphasis on PMI, improving decline in NHS admissions with tariff benefit Mix Continued shift to oncology and day case, strong growth in outpatients Costs FY effect of investment in qua

  42. Slide 42: Hospital and clinic ratings from CQC, HIW and HIS

    Hospital and clinic ratings from CQC, HIW* and HIS† Site Rating Site Rating Site Rating Site Rating Requires Alexandra Improvement Fylde Coast Good Methley Park Good Thames Valley Good Requires Brighton/MHL Outstanding Gatwick/Horley Improvement North Cheshire Outstanding Tunbridge Wells Good Bristo

Spire Healthcare Group — H1 2019 Earnings Presentation on 6ix